nach oben

Erschienen in:

27.12.2016 | Case Report

Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56− chronic lymphoproliferative disorder of NK-cells

verfasst von: Nodoka Sekiguchi, Sayaka Nishina, Toru Kawakami, Hitoshi Sakai, Noriko Senoo, Yasushi Senoo, Toshiro Ito, Hiroshi Saito, Hideyuki Nakazawa, Tomonobu Koizumi, Fumihiro Ishida

Erschienen in: International Journal of Hematology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

An 84-year-old woman was referred to our hospital presenting anemia. Her hemoglobin level was 5.8 g/dL, and white blood cell count was 9400/μL, consisting of 82% lymphocytes. Given the lymphocyte phenotype (CD2+, CD3−, CD16+, and CD56−) and negative whole blood EBV viral load, we made a diagnosis of chronic lymphoproliferative disorder of NK cells (CLPD-NK). We suspected hemolytic anemia because of the high levels of reticulocytes in the peripheral blood and the low haptoglobin value. Although the direct Coombs test was negative and there was no cold agglutination, we examined her red-blood-cell-bound IgG (RBC-IgG), which was elevated. She was diagnosed as having as Coombs-negative autoimmune hemolytic anemia (AIHA). We report the effectiveness of oral cyclophosphamide for Coombs-negative autoimmune hemolytic anemia in CLPD-NK.

Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994;84(8):2721–5.PubMed

Bible KC, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol. 1996;93(2):406–8.CrossRefPubMed

Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Momose K, et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 2014;105(3):342–6.CrossRefPubMedPubMedCentral

Kawahara S, Sasaki M, Isobe Y, Ando J, Noguchi M, Koike M, et al. Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan. Eur J Haematol. 2009;82(4):308–14.CrossRefPubMed

Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol. 2011;152(3):273–83.CrossRefPubMed

Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol. 2009;84(2):98–101.CrossRefPubMed

Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016;128(20):2465–8.CrossRefPubMedPubMedCentral

Alekshun TJ, Sokol L. Diseases of large granular lymphocytes. Cancer Control. 2007;14(2):141–50.PubMed

Huang Q, Chang KL, Gaal KK, Weiss LM. An aggressive extranodal NK-cell lymphoma arising from indolent NK-cell lymphoproliferative disorder. Am J Surg Pathol. 2005;29(11):1540–3.CrossRefPubMed

10.

Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139(4):532–44.CrossRefPubMed

11.

Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist. 2006;11(3):263–73.CrossRefPubMed

12.

Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999;106(4):960–6.CrossRefPubMed

13.

Morice WG, Leibson PJ, Tefferi A. Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis. Leuk Lymphoma. 2001;41(3–4):277–84.CrossRefPubMed

14.

Kaito K, Otsubo H, Ogasawara Y, Shimada T, Kasama K, Yahagi Y, et al. Severe aplastic anemia associated with chronic natural killer cell lymphocytosis. Int J Hematol. 2000;72(4):463–5.PubMed

15.

Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk. 2012;12(6):400–5.CrossRefPubMed

16.

Poullot E, Zambello R, Leblanc F, Bareau B, De March E, Roussel M, et al. Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. Ann Oncol. 2014;25(10):2030–5.CrossRefPubMedPubMedCentral

17.

Evans RS, Weiser RS. The serology of autoimmune hemolytic disease; observations on forty-one patients. AMA Arch Intern Med. 1957;100(3):371–99.CrossRefPubMed

18.

Kajii E, Omi T, Miura Y, Ikemoto S. A new approach for diagnosis of autoimmune hemolytic anemia. Rinsho Ketsueki. 1994;35(4):336–40.PubMed

19.

Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111(4):1010–22.CrossRefPubMed

20.

Handgretinger R, Geiselhart A, Moris A, Grau R, Teuffel O, Bethge W, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med. 1999;340(4):278–84.CrossRefPubMed

21.

Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica. 2009;94(10):1341–5.CrossRefPubMedPubMedCentral

22.

Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014;28(5):1134–6.CrossRefPubMed

23.

Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001;98(2):483–5.CrossRefPubMed

24.

Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93(10):1555–9.CrossRefPubMed

25.

Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood. 2011;117(10):2764–74.CrossRefPubMedPubMedCentral

26.

Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95(9):1534–41.CrossRefPubMedPubMedCentral

27.

Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015;29(4):886–94.PubMed

Titel: Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56− chronic lymphoproliferative disorder of NK-cells
verfasst von: Nodoka Sekiguchi
Sayaka Nishina
Toru Kawakami
Hitoshi Sakai
Noriko Senoo
Yasushi Senoo
Toshiro Ito
Hiroshi Saito
Hideyuki Nakazawa
Tomonobu Koizumi
Fumihiro Ishida
Publikationsdatum: 27.12.2016
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 6/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-016-2170-4

Springer Medizin

Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56− chronic lymphoproliferative disorder of NK-cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Predictors of vasovagal reactions during preoperative autologous blood donation: a single-institution analysis

The fibrous form of intracellular inclusion bodies in recombinant variant fibrinogen-producing cells is specific to the hepatic fibrinogen storage disease-inducible variant fibrinogen

Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects

Application of an improved flow cytometry-based NK cell activity assay in adult hemophagocytic lymphohistiocytosis

Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience

Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie